Holon, Israel – October 6, 2026 -- Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN) will join a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference, a virtual event running October 8-9, 2026.
Management confirms October 8 session with live investor webcast
The fireside chat is scheduled for Thursday, October 8, 2026, at 9:30 AM ET. A live webcast will stream via the Investor Relations events page on Compugen's website, with a replay available afterward.
Clinical-stage immuno-oncology pipeline anchors investor discussion
Compugen's AI-powered Unigen platform underpins a pipeline including COM701, an anti-PVRIG antibody in the randomized MAIA-ovarian trial for relapsed platinum-sensitive ovarian cancer. Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's anti-TIGIT program, is under development by AstraZeneca across multiple Phase 3, Phase 2 and Phase 1 trials under an exclusive license. GS-0321, licensed to Gilead, is in a Phase 1 trial conducted by Compugen targeting the IL-18 binding protein interaction.